The role of GABAb receptor mechanisms in cough: a double-blind, randomised controlled trial of Lesogaberan in chronic cough patients with positive and negative symptom association probabilities

Trial Profile

The role of GABAb receptor mechanisms in cough: a double-blind, randomised controlled trial of Lesogaberan in chronic cough patients with positive and negative symptom association probabilities

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Lesogaberan (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Acronyms GARMIN-II
  • Most Recent Events

    • 04 Apr 2017 Planned End Date changed from 16 Apr 2016 to 1 Sep 2017.
    • 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Dec 2015 Accrual to date is 20% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top